SAN FRANCISCO — The current glaucoma treatment landscape features a growing patient population, new market segments and acceptance of novel treatments, according to a speaker here.
“We know drugs have been working well. We have lots of drug options, and we’re getting new ones still,” Kristin H. Ingenito, MBA, said at Glaucoma 360 New Horizons Forum. “We’re also now adding new procedures to the mix, and those are seeing success. This is a really good, exciting space to be in.”
Reimbursement still poses a challenge to the glaucoma therapeutic market,